GlobalData: Continuous glucose monitoring devices could become main solution for US diabetes population if FDA's proposed changes to reimbursement go ahead; majority of diabetes patients currently have to undergo invasive self-testing several times a day

Sample article from our Tissue & Hygiene

November 22, 2022 (press release) –

Continuous glucose monitoring (CGM) devices could become the leading solution for a growing diabetes population in the US if the FDA’s proposed changes to reimbursement go ahead, says GlobalData. The leading data and analytics company notes that fully reimbursed CGM systems would provide relief to a huge number of diabetes patients, the majority of which currently have to undergo invasive self-testing several times a day.

James Spencer, Data Scientist at GlobalData, comments: “CGM devices currently make up a small proportion of the total glucose monitoring market—only 10% of total devices sold—but they could easily become the main glucose monitoring solution if they were reimbursed. These devices provide constant updates on glucose levels and enable diabetes patients to self-medicate only when needed. This is a vast improvement on more traditional systems, where forgetting to test just once can lead to a serious medical event.”

Companies and healthcare professionals have been pushing for much wider acceptance of CGMs.

Spencer continues: “On the company front, offering a widely accepted CGM device would be a huge opportunity to compete against older methods for glucose monitoring, leading to huge growth. However, insurance companies hold huge sway over which devices become successful due to reimbursement.”

That CGMs are not widely accepted as reimbursable devices is greatly impactful on their potential for growth, despite the benefits these devices can bring.

Spencer adds: “The potential for CGMs is supported by the current growth of Dexcom’s un-reimbursed G7 CGM. Even with such strong economic headwinds, the device is still causing huge growth for Dexcom, with around 17% growth in the US last year.”

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.